Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Platinum-based chemotherapy followed by maintenance treatment with bevacizumab and/or poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPis) is the standard first-line systemic treatment for patients with high-grade carcinomas of the ovary, fallopian tube, or peritoneum (high-grade ovarian carcinomas [HGOC]).1-6 Which patients truly benefit from PARPi maintenance remains controversial.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
